Gamma Medica deploys X-SPECT overseas
Switzerland's Center for Radiopharmaceutical Science has installed Gamma Medica's X-SPECT dual-modality pre-clinical imaging system
The Center for Radiopharmaceutical Science, a joint endeavor of the Paul Scherrer Institute (PSI), the Swiss Federal Institute of Technology (ETH Zurich), and the University Hospital in Zurich acquired what Gamma said is Europe's first X-SPECT pre-clinical imaging system on November 1.
PSI is a federal technology and multidisciplinary research center. The institute conducts research in solid-state physics, materials sciences, life sciences, and other areas. It hosts large cyclotron facilities, which enable the production of medical radionuclides for clinical and preclinical use. ETH Zurich is a science and technology university that earned its excellent national and international reputation through major achievements in research.
According to ETH/PSI Professor Roger Schibli, "We will be using the system to further our research in the areas of targeted radionuclide therapy of metastatic diseases and pre-clinical development of new SPECT tracers at our Center."
The Center for Radiopharmaceutical Science, a joint endeavor of the Paul Scherrer Institute (PSI), the Swiss Federal Institute of Technology (ETH Zurich), and the University Hospital in Zurich acquired what Gamma said is Europe's first X-SPECT pre-clinical imaging system on November 1.
PSI is a federal technology and multidisciplinary research center. The institute conducts research in solid-state physics, materials sciences, life sciences, and other areas. It hosts large cyclotron facilities, which enable the production of medical radionuclides for clinical and preclinical use. ETH Zurich is a science and technology university that earned its excellent national and international reputation through major achievements in research.
According to ETH/PSI Professor Roger Schibli, "We will be using the system to further our research in the areas of targeted radionuclide therapy of metastatic diseases and pre-clinical development of new SPECT tracers at our Center."